The GLP-1 drug market continued to expand, with Semaglutide reaching nearly $8 billion in Q1 sales and Tirzepatide at $6.15 billion, making it the fastest-growing segment
Yes, and it is strongly recommended
The biggest cons of the drug for her are: Mild constipation The cost and her reliance on health insurance Semaglutide is currently covered by the insurance Steward's husband has through his work, and she knows her access is in the hands of insurance providers
And the weight loss curve had not yet plateaued, meaning participants were likely to lose even more with continued treatment
33 Teasley St Suite 115, Alpharetta, GA 30009 youthtopiamedspa.com 3
If youre using a weight loss medication and thinking about starting treatment, were here to help you work out the safest way forward